• Something wrong with this record ?

IDH1/2 Mutations in Patients With Diffuse Gliomas: A Single Centre Retrospective Massively Parallel Sequencing Analysis

Z. Sporikova, R. Slavkovsky, L. Tuckova, O. Kalita, M. Megova Houdova, J. Ehrmann, M. Hajduch, L. Hrabalek, M. Vaverka

. 2022 ; 30 (3) : 178-183. [pub] 20220301

Language English Country United States

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc22019242

Patients below 55 years were genetically studied because the prevalence of isocitrate dehydrogenase 1 (IDH1) decreases in older patients and on grounds of cost-effectiveness, as suggested by the World Health Organization (WHO) in 2016. The aim of our study was to use novel massively parallel sequencing (MPS) approaches to examine rare variants of IDH1/2 in Czech diffuse astrocytic and oligodendroglial tumors (gliomas) patients below 55 years of age who had been immunohistochemically (IHC) diagnosed as IDH1 R132H negative. The IHC IDH1 status (wild type or mutant) of 275 tissue samples was analyzed using antibodies against the IDH1 R132H protein. Sixty-three samples of 55 years old patients with IHC IDH1 WT status were genotyped using two different MPS technologies to detect rare IDH1 and IDH2 variants. The tiered IHC (60 positive) and molecular (10 positive) approach thus revealed that 70 of the 275 samples (25%) bore IDH1/IDH2 mutations. The combined molecular and IHC approach thus revealed that 70 of the 275 samples (25%) considered in the study bore IDH1/IDH2 mutations. IHC detection of the IDH1 R132H variant should be routinely complemented with MPS to detect rare IDH1/2 variants in glioma patients below 55 years of age with negative IHC result of IDH R132H variant.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22019242
003      
CZ-PrNML
005      
20220804135448.0
007      
ta
008      
220720s2022 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1097/PAI.0000000000000997 $2 doi
035    __
$a (PubMed)35262523
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Sporikova, Zuzana $u Institute of Molecular and Translational Medicine
245    10
$a IDH1/2 Mutations in Patients With Diffuse Gliomas: A Single Centre Retrospective Massively Parallel Sequencing Analysis / $c Z. Sporikova, R. Slavkovsky, L. Tuckova, O. Kalita, M. Megova Houdova, J. Ehrmann, M. Hajduch, L. Hrabalek, M. Vaverka
520    9_
$a Patients below 55 years were genetically studied because the prevalence of isocitrate dehydrogenase 1 (IDH1) decreases in older patients and on grounds of cost-effectiveness, as suggested by the World Health Organization (WHO) in 2016. The aim of our study was to use novel massively parallel sequencing (MPS) approaches to examine rare variants of IDH1/2 in Czech diffuse astrocytic and oligodendroglial tumors (gliomas) patients below 55 years of age who had been immunohistochemically (IHC) diagnosed as IDH1 R132H negative. The IHC IDH1 status (wild type or mutant) of 275 tissue samples was analyzed using antibodies against the IDH1 R132H protein. Sixty-three samples of 55 years old patients with IHC IDH1 WT status were genotyped using two different MPS technologies to detect rare IDH1 and IDH2 variants. The tiered IHC (60 positive) and molecular (10 positive) approach thus revealed that 70 of the 275 samples (25%) bore IDH1/IDH2 mutations. The combined molecular and IHC approach thus revealed that 70 of the 275 samples (25%) considered in the study bore IDH1/IDH2 mutations. IHC detection of the IDH1 R132H variant should be routinely complemented with MPS to detect rare IDH1/2 variants in glioma patients below 55 years of age with negative IHC result of IDH R132H variant.
650    _2
$a senioři $7 D000368
650    12
$a nádory mozku $x diagnóza $7 D001932
650    12
$a gliom $x patologie $7 D005910
650    _2
$a vysoce účinné nukleotidové sekvenování $7 D059014
650    _2
$a lidé $7 D006801
650    _2
$a isocitrátdehydrogenasa $x genetika $x metabolismus $7 D007521
650    _2
$a lidé středního věku $7 D008875
650    _2
$a mutace $7 D009154
650    _2
$a retrospektivní studie $7 D012189
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Slavkovsky, Rastislav $u Institute of Molecular and Translational Medicine
700    1_
$a Tuckova, Lucie $u Departments of Clinical and Molecular Pathology
700    1_
$a Kalita, Ondrej $u Neurosurgery, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc $u Department of Health Care Science, Faculty of Humanities, T. Bata University in Zlin, the Czech Republic
700    1_
$a Megova Houdova, Magdalena $u Institute of Molecular and Translational Medicine
700    1_
$a Ehrmann, Jiri $u Departments of Clinical and Molecular Pathology
700    1_
$a Hajduch, Marian $u Institute of Molecular and Translational Medicine
700    1_
$a Hrabalek, Lumir $u Neurosurgery, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc
700    1_
$a Vaverka, Miroslav $u Neurosurgery, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc
773    0_
$w MED00005735 $t Applied immunohistochemistry & molecular morphology : AIMM $x 1533-4058 $g Roč. 30, č. 3 (2022), s. 178-183
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35262523 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220720 $b ABA008
991    __
$a 20220804135442 $b ABA008
999    __
$a ok $b bmc $g 1822719 $s 1170485
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 30 $c 3 $d 178-183 $e 20220301 $i 1533-4058 $m Applied immunohistochemistry & molecular morphology $n Appl. immunohistochem. mol. morphol. (Print) $x MED00005735
LZP    __
$a Pubmed-20220720

Find record

Citation metrics

Archiving options